Innate Pharma Presents Promising Preclinical Data for IPH4502 at AACR 2025

Innate Pharma shared preclinical findings for its antibody drug conjugate (ADC) IPH4502 at the AACR 2025 Annual Meeting. IPH4502, targeting Nectin-4, exhibited notable preclinical anti-tumor efficacy across various cancers, including urothelial carcinoma and triple-negative breast cancer, particularly in models resistant to enfortumab vedotin (EV).

IPH4502 is currently under Phase 1 clinical trial for advanced solid tumors. The study aims to evaluate its safety and efficacy. The results suggest a potential broader clinical application, especially in cancers with low Nectin-4 expression. Sonia Quaratino, Chief Medical Officer of Innate, expressed optimism about the ongoing trial and anticipated sharing clinical data in 2026.